prikaz prve stranice dokumenta Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams
Pristup korisnicima matične ustanove
Znanstveni rad - Izvorni znanstveni rad
Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams
Medical Hypotheses, 193 (2024); 111510. https://doi.org/10.1016/j.mehy.2024.111510
Stanić Damić, Marija; Valković, Toni; Petranović, Duška; Belančić, Andrej; Perić, Zinaida

Citirajte ovaj rad

Stanić Damić, M., Valković, T., Petranović, D., Belančić, A. i Perić, Z. (2024). Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams. Medical Hypotheses, 193.. doi: 10.1016/j.mehy.2024.111510

Stanić Damić, Marija, et al. "Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams." Medical Hypotheses, vol. 193, 2024. https://doi.org/10.1016/j.mehy.2024.111510

Stanić Damić, Marija, Toni Valković, Duška Petranović, Andrej Belančić i Zinaida Perić. "Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams." Medical Hypotheses 193 (2024). https://doi.org/10.1016/j.mehy.2024.111510

Stanić Damić, M., et al. (2024) 'Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams', Medical Hypotheses, 193. doi: 10.1016/j.mehy.2024.111510

Stanić Damić M, Valković T, Petranović D, Belančić A, Perić Z. Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams. Medical Hypotheses [Internet]. 01.12.2024. [pristupljeno 05.12.2024.];193. doi: 10.1016/j.mehy.2024.111510

M. Stanić Damić, T. Valković, D. Petranović, A. Belančić i Z. Perić, "Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams", Medical Hypotheses, vol. 193, Prosinac 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:967462. [Citirano: 05.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:967462
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Bortezomib-based regimen affects cognitive functions in multiple myeloma patients through the VEGF pathway – Hypothesis that connects different knowledge streams
AutorMarija Stanić Damić
AutorToni Valković
AutorDuška Petranović
AutorAndrej Belančić
AutorZinaida Perić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za farmakologiju)
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Klinička farmakologija s toksikologijom
Sažetak (engleski)
Multiple myeloma is a chronic hematological malignancy that usually affects older adults. Cancer-related cognitive impairment in multiple myeloma patients significantly impacts the everyday quality of life, however its pathophysiology remains poorly understood. Bortezomib is a commonly used drug in the treatment of multiple myeloma that does not pass the blood–brain barrier. Nevertheless, it can still affect central nervous system (CNS) through yet unknown mechanisms. This article discusses the potential effect of bortezomib-based treatment on cognitive functions in multiple myeloma patients. We hypothesize that bortezomib impairs cognition by decreasing the levels of a neuroprotective cytokine – vascular endothelial growth factor (VEGF). The generation of hypotheses about the pathophysiology of cognitive impairment paves the way for future basic and clinical studies to improve multiple myeloma management. VEGF could serve as a biomarker of cognitive dysfunction while systematic evaluation of cognition could enable early detection of cognitive impairment. Timely recognition of cognitive impairment might be crucial when selecting the most appropriate treatment. Furthermore, this could allow the implementation of preventive measures against further deterioration in cognitive function and quality of life for patients with multiple myeloma.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaMedical Hypotheses
Brojčani podacivol. 193, 111510
p-ISSN0306-9877
DOIhttps://doi.org/10.1016/j.mehy.2024.111510
URN:NBNurn:nbn:hr:184:967462
Datum objave publikacije2024-12-01
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S0306987724002536
Vrsta resursaTekst
Prava pristupaInstitucijski pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-12-04 11:45:36